XM does not provide services to residents of the United States of America.
I
I

Ipsen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis

BRIEF-Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis Ipsen SA IPN.PA : IPSEN’S IQIRVO® RECEIVES U.S. FDA ACCELERATED APPROVAL AS A FIRST-IN-CLASS PPAR TREATMENT FOR PRIMARY BILIARY CHOLANGITIS IPSEN SA - IQIRVO MAY BE PRESCRIBED IMMEDIATELY IN U.S. FOR ELIGIBLE PATIENTS.
I

US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug

UPDATE 3-US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug Adds details on pricing in paragraph 3, background throughout By Puyaan Singh and Mariam Sunny June 10 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug for a chronic inflammatory liver disease, Iqirvo, the companies said on Monday.
G
I

US FDA approves Genfit and Ipsen's liver disease drug

US FDA approves Genfit and Ipsen's liver disease drug June 10 (Reuters) - The U.S. Food and Drug Administration has approved French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug to treat a chronic inflammatory liver disease, Ipsen said on Monday. Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona
I

Ipsen Initiates Share Buy-Back Program

BRIEF-Ipsen Initiates Share Buy-Back Program June 3 (Reuters) - Ipsen SA IPN.PA : IPSEN INITIATES A SHARE BUY-BACK PROGRAM TO COVER ITS FREE EMPLOYEE SHARE-ALLOCATION PLAN IPSEN APPOINTED AN INVESTMENT-SERVICES PROVIDER TO PURCHASE AN AGGREGATE NUMBER OF IPSEN S.A. SHARES UP TO 400,000, OR ABOUT 0.47% OF SHARE CAPITAL HAS APPOINTED AN INVESTMENT-SERVICES PROVIDER TO PURCHASE AN AGGREGATE NUMBER OF IPSEN S.A.
I

Genfit Q1 Revenue Falls to EUR 1.1 Million

BRIEF-Genfit Q1 Revenue Falls to EUR 1.1 Million May 15 (Reuters) - Genfit SA GNFT.PA : REPORTED ON TUESDAY FIRST QUARTER 2024 FINANCIAL INFORMATION REVENUES FOR FIRST THREE MONTHS OF 2024 AMOUNTED TO EUR 1.1 MILLION COMPARED TO EUR 5.0 MILLION FOR SAME PERIOD IN 2023 AS OF MARCH 31, 2024, CO’S CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 74.0 MLN V
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.